Syngene International Limited

8%

ngene’s position in the fastest growing segment of the global CRDMO market Market size* (USD bn) 8% CAGR 144 22 99 23 2023 213 39 137 37 2028 Value Buy State of the art facility acquired a

Rs 617 Crore

AGR 144 22 99 23 2023 213 39 137 37 2028 Value Buy State of the art facility acquired at Rs 617 Crores (USD 75 Mn) fully funded through internal accruals and cash CRO SM CDMO LM CDMO Overall CRDMO

1x

Guidance given at time of acquisition. We are maintaining the guidance for now Asset turnover of 1x in less than 5 years $75m acquisition price (Acquisition concluded at gross value of Rs 617 cror

Rs 617 crore

rnover of 1x in less than 5 years $75m acquisition price (Acquisition concluded at gross value of Rs 617 crores. Value buy as company recorded Capital reserve due to purchase price < fair value of facility) $

INR 100 Crore

ecorded Capital reserve due to purchase price < fair value of facility) $10m modification capex (INR 100 Crores to repurpose and revalidate the facility) $85m to operationalise Operating Margin Minor dilut

250 million

) : • Commercial scale, high speed, fill-finish unit • 2 integrated vials lines: 520 vials/min • 250 million vials annual capacity at 2 mL fill volume • 2-100 mL fill volume feasibility • 2 new isolator lin